The JAK inhibitor tofacitinib has been reported to inhibit TNF-induced, type I interferon-mediated, chemokine expression in RA-FLS [23, 24], but other effects on these cells remain incompletely characterized. This evidence concerns the gene TNF and rheumatoid arthritis.